Strs Ohio Increases Stock Position in Repligen Corporation $RGEN

Strs Ohio boosted its position in shares of Repligen Corporation (NASDAQ:RGEN) by 8.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,760 shares of the biotechnology company’s stock after purchasing an additional 4,498 shares during the period. Strs Ohio’s holdings in Repligen were worth $6,452,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC acquired a new position in Repligen in the 3rd quarter worth $29,000. Bayforest Capital Ltd acquired a new stake in shares of Repligen during the fourth quarter valued at about $32,000. Rachor Investment Advisory Services LLC acquired a new stake in shares of Repligen during the fourth quarter valued at about $33,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the fourth quarter valued at about $36,000. Finally, Farther Finance Advisors LLC increased its position in shares of Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on RGEN shares. Royal Bank Of Canada assumed coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target for the company. Jefferies Financial Group restated a “hold” rating and set a $142.00 price objective on shares of Repligen in a report on Tuesday, May 5th. Wolfe Research started coverage on Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Barclays increased their target price on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Insider Activity

In related news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Repligen Price Performance

NASDAQ:RGEN opened at $142.40 on Monday. The company has a market capitalization of $8.03 billion, a price-to-earnings ratio of 158.22, a price-to-earnings-growth ratio of 2.74 and a beta of 1.06. Repligen Corporation has a one year low of $100.99 and a one year high of $175.77. The stock has a 50-day simple moving average of $123.84 and a 200 day simple moving average of $134.61. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.25 million during the quarter, compared to analyst estimates of $192.05 million. During the same period in the previous year, the company earned $0.39 earnings per share. Repligen’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts predict that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.